FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Stock analysts at Brookline Capital Management dropped their FY2028 earnings per share estimates for shares of C4 Therapeutics in a research report issued to clients and investors on Wednesday, January 14th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn $0.13 per share for the year, down from their prior estimate of $1.15. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share. Brookline Capital Management also issued estimates for C4 Therapeutics’ FY2029 earnings at $7.22 EPS and FY2030 earnings at $26.65 EPS.

Other equities research analysts have also recently issued reports about the company. Stephens reissued an “overweight” rating and set a $6.00 price objective on shares of C4 Therapeutics in a research note on Monday, September 22nd. Cowen started coverage on C4 Therapeutics in a report on Tuesday, December 2nd. They set a “buy” rating on the stock. Barclays lowered their price target on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their price target on shares of C4 Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 23rd. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.25.

C4 Therapeutics Stock Up 0.7%

C4 Therapeutics stock opened at $2.24 on Monday. The company’s 50-day moving average price is $2.32 and its 200-day moving average price is $2.37. The company has a market cap of $216.59 million, a PE ratio of -1.34 and a beta of 2.93. C4 Therapeutics has a twelve month low of $1.09 and a twelve month high of $4.03.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 64.40%. The company had revenue of $11.23 million for the quarter, compared to analysts’ expectations of $6.28 million.

Institutional Investors Weigh In On C4 Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CCCC. Brookstone Capital Management bought a new stake in shares of C4 Therapeutics during the second quarter valued at approximately $42,000. Goldman Sachs Group Inc. grew its stake in C4 Therapeutics by 8.6% in the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company’s stock worth $996,000 after purchasing an additional 49,065 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in C4 Therapeutics during the 2nd quarter worth $31,000. Y Intercept Hong Kong Ltd bought a new stake in C4 Therapeutics during the 2nd quarter valued at $75,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of C4 Therapeutics in the 2nd quarter worth $40,000. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.